Hepion Pharmaceuticals Inc (NASDAQ:HEPA) shares, rose in value on Wednesday, April 16, with the stock price down by -2.00% to the previous day’s close as strong demand from buyers drove the stock to $0.34.
Actively observing the price movement in the last trading, the stock closed the session at $0.35, falling within a range of $0.34 and $0.3731. The value of beta (5-year monthly) was 1.797. Referring to stock’s 52-week performance, its high was $112.00, and the low was $0.34. On the whole, HEPA has fluctuated by -56.14% over the past month.
With the market capitalization of Hepion Pharmaceuticals Inc currently standing at about $3.76 million, investors are eagerly awaiting this quarter’s results, scheduled for on 2024-Apr-15.
Technical indicators serve as essential tools for traders, offering insights into market sentiment and potential price movements. We see that HEPA’s technical picture suggests that short-term indicators denote the stock is a 100% Sell on average. However, medium-term indicators have put the stock in the category of 100% Sell while long-term indicators on average have been pointing out that it is a 100% Sell.
The stock’s technical analysis shows that the price of HEPA currently trading nearly -34.45% and -91.22% away from the simple moving averages for 20 and 50 days respectively. The Relative Strength Index (RSI, 14) currently indicates a reading of 20.97, while the 7-day volatility ratio is showing 20.19% which for the 30-day chart, stands at 28.90%. Furthermore, Hepion Pharmaceuticals Inc (HEPA)’s beta value is 1.87, and its average true range (ATR) is 0.36.
A comparison of Hepion Pharmaceuticals Inc (HEPA) with its peers suggests the former has fared considerably weaker in the market. HEPA showed an intraday change of -2.00% in last session, and over the past year, it shrunk by -99.69%%.
Data on historical trading for Hepion Pharmaceuticals Inc (NASDAQ:HEPA) indicates that the trading volumes over the past 10 days have averaged 12.26 and over the past 3 months, they’ve averaged 4.09 million. According to company’s latest data on outstanding shares, there are 10.98 million shares outstanding.
Nearly 0.48% of Hepion Pharmaceuticals Inc’s shares belong to company insiders and institutional investors own 0.28% of the company’s shares. The data on short interest also indicates that stock shorts accounted for 0.2 million shares as on 2025-03-31, resulting in a short ratio of 0.1. According to the data, the short interest in Hepion Pharmaceuticals Inc (HEPA) stood at 1850.00 of shares outstanding as of 2025-03-31; the number of short shares registered in 2025-02-28 reached 83200.0. The stock has fallen by -98.54% since the beginning of the year, thereby showing the potential of a further growth. This could raise investors’ confidence to be optimistic about the HEPA stock heading into the next quarter.
